• Users Online: 174
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2016  |  Volume : 10  |  Issue : 3  |  Page : 61-64

Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study


MIOT Institute of Nephrology, MIOT International, Chennai, Tamil Nadu, India

Correspondence Address:
B Kirushnan
MIOT Institute of Nephrology, MIOT International, 4/112, Mount Poonamallee Road, Manapakkam, Chennai 600089
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.ijt.2016.05.003

Get Permissions

Aim: To study the efficacy and tolerability of sofosbuvir and ribavirin in post renal transplant patients with chronic hepatitis C infection. Methods: Data of 20 hepatitis C positive patients who had a negative viral load prior to renal transplant were analysed. They were given treatment with sofosbuvir 400 mg/day and dose adjusted ribavirin for 12 weeks, when they were found to have viraemia after transplant. Viral load was monitored at 4 weeks, 16 weeks and 24 weeks after initiation of therapy. Results: 12 patients had genotype 1, 6 patients had genotype 3 and only 1 patient had genotype 4. 1 patient had mixed genotype infection. The median viral load was 3,394,705 IU/ml. Virological response was assessed at 4 weeks, 16 weeks and 24 weeks after treatment initiation. Rapid virological response (RVR) was seen in 19 patients (95%). Virological response at 4 weeks after treatment completion (SVR 4) was seen in 19 (95%) patients. Data were available for 13 patients who completed follow-up for 12 weeks after treatment completion. The remaining patients discontinued the drugs due to financial reasons. Sustained virological response at 12 weeks after treatment completion (SVR 12) was seen in 10 out of the 13 patients (76.9%). 3 patients did not attain SVR 12 and were regarded as treatment failure. The drugs were well tolerated in the majority. 1 patient required erythropoietin temporarily after ribavirin therapy. Conclusion: Sofosbuvir and ribavirin showed a good efficacy and tolerability when used in renal transplant recipients. However, the genotype, nature of underlying liver disease, duration of therapy play an important factor in deciding the response to therapy.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed376    
    Printed15    
    Emailed0    
    PDF Downloaded76    
    Comments [Add]    
    Cited by others 2    

Recommend this journal